This company has been marked as potentially delisted and may not be actively trading. XORTX Therapeutics (XRTX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock XRTX vs. CTXR, MRKR, IXHL, PRPH, CARM, TXMD, ERNA, PHIO, BIVI, and LYRAShould you be buying XORTX Therapeutics stock or one of its competitors? The main competitors of XORTX Therapeutics include Citius Pharmaceuticals (CTXR), Marker Therapeutics (MRKR), Incannex Healthcare (IXHL), ProPhase Labs (PRPH), Carisma Therapeutics (CARM), TherapeuticsMD (TXMD), Ernexa Therapeutics (ERNA), Phio Pharmaceuticals (PHIO), BioVie (BIVI), and Lyra Therapeutics (LYRA). These companies are all part of the "med - drugs" industry. XORTX Therapeutics vs. Its Competitors Citius Pharmaceuticals Marker Therapeutics Incannex Healthcare ProPhase Labs Carisma Therapeutics TherapeuticsMD Ernexa Therapeutics Phio Pharmaceuticals BioVie Lyra Therapeutics Citius Pharmaceuticals (NASDAQ:CTXR) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership. Do analysts prefer CTXR or XRTX? Citius Pharmaceuticals presently has a consensus price target of $53.00, indicating a potential upside of 3,915.15%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Citius Pharmaceuticals is more favorable than XORTX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50XORTX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, CTXR or XRTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius PharmaceuticalsN/AN/A-$39.14MN/AN/AXORTX TherapeuticsN/AN/A-$3.31M-$1.35-0.66 Is CTXR or XRTX more profitable? XORTX Therapeutics' return on equity of -36.38% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Citius PharmaceuticalsN/A -60.03% -33.83% XORTX Therapeutics N/A -36.38%-24.45% Which has more volatility & risk, CTXR or XRTX? Citius Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, XORTX Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Do insiders & institutionals have more ownership in CTXR or XRTX? 16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 10.7% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer CTXR or XRTX? In the previous week, Citius Pharmaceuticals had 6 more articles in the media than XORTX Therapeutics. MarketBeat recorded 11 mentions for Citius Pharmaceuticals and 5 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 0.00 beat Citius Pharmaceuticals' score of -0.07 indicating that XORTX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral XORTX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCitius Pharmaceuticals beats XORTX Therapeutics on 7 of the 11 factors compared between the two stocks. Get XORTX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XRTX vs. The Competition Export to ExcelMetricXORTX TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.64M$2.48B$5.69B$9.81BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-3.0721.8230.6725.54Price / SalesN/A747.75463.88116.75Price / CashN/A184.4138.2159.48Price / Book1.014.888.986.13Net Income-$3.31M$31.61M$3.25B$264.89M XORTX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XRTXXORTX Therapeutics0.2223 of 5 stars$0.89+1.1%N/A-40.1%$4.64MN/A-3.07N/AShort Interest ↓Gap UpCTXRCitius Pharmaceuticals2.8719 of 5 stars$1.35-2.9%$53.00+3,825.9%-91.1%$14.78MN/A0.0020News CoverageEarnings ReportAnalyst ForecastShort Interest ↓MRKRMarker Therapeutics3.871 of 5 stars$1.25+0.8%$13.17+953.3%-62.2%$14.03M$6.59M-0.9460Earnings ReportShort Interest ↑Gap UpIXHLIncannex Healthcare0.3756 of 5 stars$0.41-8.6%N/A-78.6%$13.09M$10K-0.343Short Interest ↑Gap DownPRPHProPhase Labs1.1035 of 5 stars$0.31-0.8%N/A-86.7%$12.88M$6.77M-0.24130Earnings ReportGap DownCARMCarisma Therapeutics3.0194 of 5 stars$0.31+0.6%$1.93+521.0%-71.8%$12.87M$19.63M-0.2020Short Interest ↓TXMDTherapeuticsMD0.501 of 5 stars$1.10flatN/A-29.0%$12.73M$1.76M0.00420Earnings ReportERNAErnexa Therapeutics0.6533 of 5 stars$1.69+8.3%N/A-93.8%$11.49M$580K-0.2010Earnings ReportShort Interest ↑PHIOPhio Pharmaceuticals2.85 of 5 stars$2.35-0.8%$14.00+495.7%-15.6%$11.37MN/A-0.3710News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap DownBIVIBioVie0.7835 of 5 stars$4.96-17.3%N/A-92.5%$11.16MN/A-0.0610Upcoming EarningsGap UpHigh Trading VolumeLYRALyra Therapeutics2.991 of 5 stars$6.75-1.2%$100.00+1,381.5%-50.5%$10.92M$1.53M-0.1150News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap Down Related Companies and Tools Related Companies CTXR Alternatives MRKR Alternatives IXHL Alternatives PRPH Alternatives CARM Alternatives TXMD Alternatives ERNA Alternatives PHIO Alternatives BIVI Alternatives LYRA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XRTX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XORTX Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XORTX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access